Approaches to Individualized Treatment for Chronic Lymphocytic Leukemia: Expert Guidance on Sequencing Therapy, Novel Agents, and Their Combinations

Download these slides from our live satellite symposium on CLL to review the most recent clinical data on new agents in both frontline and relapsed/refractory CLL.
Jeremy S. Abramson, MD, MMSc
William G. Wierda, MD, PhD
Format: Microsoft PowerPoint (.ppt)
File Size: 3.66 MB
Released: September 26, 2019

Acknowledgements

Provided by the National Comprehensive Cancer Network in partnership with Clinical Care Options, LLC
NCCN Logo

Karen Kanefield
Manager CE Accreditation & Program Operations
National Comprehensive Cancer Network
3025 Chemical Road, Suite 100
Plymouth Meeting, PA 19462

215-690-0239
215-690-0283 (Fax)
gianola@nccn.org
For Clinicians:
NCCN.org
For Patients:
NCCN.org/patients

This activity is supported by an educational grant from AstraZeneca.

This activity is supported by an independent medical education grant from Pharmacyclics LLC and Janssen.

Related Content

Commentary on pharmacist’s role in preventing, identifying, and caring for patients experiencing CAR T-cell–associated acute and long-term toxicities.

Shilpa Paul Headshot Shilpa Paul, PharmD, BCOP Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: February 17, 2020 Expiration: February 16, 2021

CME-certified interactive virtual presentation from Clinical Care Options (CCO) with case-based expert insights on using targeted therapies for treating patients with CLL

Jeff P. Sharman, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: February 14, 2020 Expiration: February 13, 2021

Downloadable slides on the most recent clinical data on targeted therapies in CLL from Clinical Care Options (CCO).

Jeff P. Sharman, MD Released: February 14, 2020

Expert responses to clinical questions on treatment challenges in peripheral T-cell lymphomas from a Clinical Care Options (CCO) PTCL symposium at ASH 2019

Steven M. Horwitz, MD Released: February 7, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?